Omega cuts 35% of work­force; Rhythm, Cer­voMed, Sur­rozen raise new fund­ing

Plus: Treve­na’s strate­gic re­view for its com­mer­cial drug, Al­ger­non’s new fo­cus and An­tibe Ther­a­peu­tics’ clin­i­cal hold.

Omega Ther­a­peu­tics cuts 35% of work­force: The biotech had 93 em­ploy­ees at the end of 2023. Omega al­so pri­or­i­tized its pipeline, but the move does not im­pact the pact it re­cent­ly inked with No­vo Nordisk. — Kyle LaHu­cik

Treve­na seeks to of­fload com­mer­cial as­set: The pen­ny stock biotech says it has re­duced com­mer­cial sup­port to Olin­vyk to pre­serve cap­i­tal. It’s seek­ing strate­gic al­ter­na­tives for the opi­oid drug. In­stead, it will fo­cus re­sources on its S1P re­cep­tor mod­u­la­tor, TRV045. — Am­ber Tong

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER